Formulary Drug Review: Ocrelizumab.

Each month, subscribers to receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services.

Formulary Drug Review: Edaravone.

Each month, subscribers to receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services.

CYP2C9 polymorphisms: considerations in NSAID therapy.

The increased focus on safety in clinical trials represents a formidable hurdle regarding the availability of marketed drugs. The lengthy experimental process of ensuring the safety of a drug creates a need for faster, more efficient identification of drug toxicities. Profiling for individual genetic variability could be an essential screening process for potential adverse effects, especially within different ethnic populations.